News
The eye health company Bausch + Lomb announced on Monday that it is recalling several of its intraocular lenses due to safety concerns. The company said it was recalling several of its enVista ...
Bausch + Lomb has recalled lenses used during cataract surgery due to complications when the lenses are used, according to an announcement from the Canada-based eyecare company posted on the U.S ...
Shares of eyecare company Bausch + Lomb (NYSE:BLCO) fell 10.6% in the afternoon session after the company announced the voluntary recall of intraocular lenses on its enVista platform. The recall ...
Eye health company Bausch & Lomb is recalling some of its intraocular lenses over possible safety concerns. The voluntary recall comes after the company “received reports of complications ...
Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb conducted an investigation and identified the cause and affected lots of the IOLs. Full market ...
March 27 (Reuters) - Bausch + Lomb (BLCO.TO), opens new tab said on Thursday it will recall some of its implantable eye lenses after receiving reports of complications, the cause of which could ...
NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such investors ...
Eyecare company Bausch + Lomb (NYSE:BLCO) will be reporting earnings tomorrow before market open. Here’s what you need to know. Bausch + Lomb beat analysts’ revenue expectations by 1.8% last ...
Please provide your email address to receive an email when new articles are posted on . Bausch + Lomb has received reports of toxic anterior segment syndrome in patients with enVista IOLs.
Hosted on MSN1mon
Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out forFor the last reported quarter, it was expected that Bausch + Lomb would post earnings of $0.24 per share when it actually produced earnings of $0.25, delivering a surprise of +4.17%.
Fitch Ratings upgraded its credit grade on both Bausch + Lomb Corp. and its parent company Bausch Health Cos., but said the eye care unit’s ratings will continue to be under pressure unless the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results